• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Twelve Italian cases reveal variable hypophosphatasia phenotype

by
November 17, 2026
in Health
Reading Time: 5 mins read
0
Twelve Italian cases reveal variable hypophosphatasia phenotype

Twelve Italian cases reveal variable hypophosphatasia phenotype

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers from multiple Italian medical institutions have reported the clinical, molecular, and functional characterization of twelve individuals with hypophosphatasia, a rare inborn error of bone metabolism. The study, published in Frontiers in Endocrinology, highlights the extreme variability of the disease, which can range from severe infantile presentations to completely asymptomatic biochemical findings. By combining clinical reviews with advanced genetic and in vitro assays, the team demonstrated that many individuals carry pathogenic variants in the ALPL gene without exhibiting the typical skeletal or dental symptoms associated with the condition. This finding underscores the diagnostic challenges posed by the disease’s wide phenotypic spectrum and the frequent delay in reaching a definitive molecular diagnosis.

Hypophosphatasia is caused by pathogenic variants in the ALPL gene, which encodes tissue non-specific alkaline phosphatase, an enzyme critical for bone mineralization and nervous system development. The condition is characterized by a broad range of clinical severity, often correlated with the levels of residual enzymatic activity. The research team enrolled twelve patients from tertiary care centers across Northern, Middle, and Southern Italy, as well as Sardinia. These individuals were referred for genetic analysis primarily due to persistently low serum alkaline phosphatase levels, a biochemical hallmark of the disease, or because of severe bone fragility phenotypes that initially suggested other conditions such as osteogenesis imperfecta.

The clinical presentations among the twelve patients were highly heterogeneous. Four cases were diagnosed with infantile hypophosphatasia, while one was classified as adult-onset. Notably, four individuals were completely asymptomatic, identified only through routine biochemical screening that revealed low alkaline phosphatase values. Three other patients presented with symptoms that were not strictly related to hypophosphatasia, such as growth delay, neuromotor developmental issues, or spondylo-osteoarthritis. One patient presented a particularly challenging case, exhibiting classic signs of hypophosphatasia including multiple fractures and edentulia, yet maintaining normal alkaline phosphatase levels, which initially led clinicians to suspect osteogenesis imperfecta.

Molecular analysis using next-generation sequencing identified twelve pathogenic or likely pathogenic variants, all present in heterozygosity. These included nine missense variants, two in-frame indels, and one multiexonic deletion. One of the missense variants, p.(Pro174Leu), and the multiexonic deletion were novel findings, expanding the known mutational spectrum of the ALPL gene. The variants were classified according to the American College of Medical Genetics and Genomics recommendations. Segregation analysis in available family members confirmed the inheritance patterns, with some asymptomatic relatives carrying the same variants, suggesting a complex relationship between genotype and clinical expression.

To understand the functional impact of these variants, the researchers performed in vitro characterization of seven point variants that lacked previously described functional data. Western blot analysis revealed that most mutant proteins showed significantly decreased expression levels compared to the wild-type enzyme. Specifically, four mutants were barely expressed, indicating a loss or down-regulation of the protein. However, the novel p.(Pro174Leu) variant appeared to be normally expressed at the protein level, suggesting that its functional impairment might stem from a different mechanism, such as interference with catalytic activity rather than protein stability.

Colorimetric assays measuring enzymatic activity confirmed a dramatic decrease in function for most of the tested mutants. These in vitro results demonstrated that even in patients with mild or absent clinical symptoms, the mutant enzymes were often almost totally inactive. This discrepancy between severe biochemical impairment and mild clinical presentation remains a key puzzle in understanding the pathophysiology of hypophosphatasia, potentially involving compensatory physiological factors or other genetic modifiers not captured in routine screening.

In silico structural predictions provided further insights into the mechanisms of dysfunction. Using Missense3D and FoldX, the researchers assessed the structural and thermodynamic stability of the mutant proteins. Missense3D identified p.(Gly491Arg) as damaging due to the substitution of a glycine in a structural bend. FoldX analysis revealed significant destabilizing effects for p.(Pro307Leu), p.(Arg272His), and p.(Pro174Leu), with positive delta-delta-G values indicating reduced protein stability. These computational findings were consistent with the observed reduction in residual enzymatic activity and protein expression, offering a molecular basis for the functional deficits observed in the laboratory.

The study highlights the significant delays in diagnosis, which ranged from 3 to 65 years for atypical cases and up to 40 years for those with suggestive clinical spectra. This prolonged diagnostic odyssey often leads to mismanagement and potential harm from inappropriate treatments, such as antiresorptive therapies that are contraindicated in hypophosphatasia. The authors emphasize that persistently low alkaline phosphatase levels should be a strong indicator for genetic testing, even in the absence of overt clinical signs. Increased clinical awareness and attention to these biochemical markers are crucial for achieving earlier and more accurate diagnoses, particularly in asymptomatic individuals who may be at risk of developing symptoms over time.

From a therapeutic perspective, the authors suggest that enzyme replacement therapy could be beneficial for symptomatic patients with frank biochemical and skeletal manifestations. The study also notes that genetic counseling poses challenges due to the multiple inheritance modes, extreme phenotypic variability, and the widespread prevalence of hypomorphic ALPL alleles in the general population. Managing these individuals as having subclinical hypophosphatasia, while avoiding antiresorptive treatments, is recommended as a precautionary measure.

The researchers acknowledge several limitations, including the small sample size and the unavailability of certain biochemical data, such as vitamin B6 levels and Z-scores, for most patients. There is also the potential for selection or referral bias from the involved tertiary care centers. Longitudinal follow-up is necessary to determine whether asymptomatic individuals will develop a full clinical spectrum of the disease. Despite these limitations, the findings align with recent retrospective analyses that have identified a growing number of genetically confirmed cases with only a biochemical phenotype, suggesting that asymptomatic hypophosphatasia may be more common than previously recognized.

This work expands the knowledge of ALPL variant impacts on protein structure and enzymatic function, providing a clearer picture of the molecular underpinnings of the disease. The increasing use of whole-exome sequencing in routine diagnostic practice is likely to identify more individuals carrying ALPL variants, many of whom may be asymptomatic. Understanding the pathophysiology of these cases is essential for developing appropriate management strategies and preventing misdiagnosis. The study reinforces the need for a multidisciplinary approach to hypophosphatasia, integrating clinical, biochemical, and genetic data to navigate the complex diagnostic landscape.

The findings contribute to the broader understanding of rare bone disorders and the importance of biochemical markers in diagnosis. By documenting the functional consequences of novel and known variants, the researchers provide a valuable resource for future studies and clinical practice. The case of the patient with normal alkaline phosphatase levels but classic clinical signs further complicates the diagnostic scenario, highlighting the need for comprehensive molecular testing in cases of severe bone fragility. As the field moves forward, continued research into the mechanisms of phenotypic variability will be key to improving patient outcomes and quality of life.

In conclusion, the study of these twelve Italian cases illustrates the challenging nature of diagnosing hypophosphatasia, particularly in individuals with atypical or asymptomatic presentations. The combination of clinical, molecular, and functional data provides a comprehensive view of the disease’s complexity. By identifying novel variants and characterizing their functional impact, the researchers have advanced the understanding of ALPL-related pathology. This work underscores the importance of maintaining a high index of suspicion for hypophosphatasia in patients with unexplained low alkaline phosphatase levels or bone fragility, ensuring timely and accurate diagnosis and management.

Subject of Research: Clinical and molecular characterization of hypophosphatasia in twelve Italian patients

Article Title: Twelve novel Italian cases of hypophosphatasia: challenging cases with an extremely variable phenotype

Article References: Casamassima, G., Biagini, T., Pugliese, F., Grieco, A. M., Petrizzelli, F., Mazza, T., Celli, M., Scarano, E., Tamburrino, F., Colangelo, L., Eller-Vainicher, C., Naciu, A. M., Tabacco, G., Rossini, G., Pigliaru, F., Palermo, A., Morlino, S., Augello, B., Petracca, A., … Guarnieri, V. (2026). Twelve novel Italian cases of hypophosphatasia: challenging cases with an extremely variable phenotype. Frontiers in Endocrinology, 17, Article 1966666. https://doi.org/10.3389/fendo.2026.1966666

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1966666

Keywords: hypophosphatasia, ALPL gene, bone metabolism, genetic variants, alkaline phosphatase, rare disease, clinical diagnosis, in vitro assays, in silico prediction, Italy, Twelve, novel

News Source: Ophelia Keating. (November 17, 2026). Twelve Italian cases reveal variable hypophosphatasia phenotype. Scienmag.

Tags: alkaline phosphataseALPL genebone metabolismclinical diagnosisGenetic Variantshypophosphatasiain silico predictionin vitro assaysItalynovelrare diseaseTwelve
Share12Tweet7Share2ShareShareShare1

Related Posts

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

November 17, 2026
Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

November 17, 2026

Review finds disease prevention guidance prioritizes genetic risk over modifiable factors

November 17, 2026

Study Finds Only Sixteen Percent of Ethiopian Mothers Complete Continuum of Care

November 17, 2026

POPULAR NEWS

  • Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    29 shares
    Share 12 Tweet 7
  • Quality Improvement Project Raises Pre-Antibiotic Microbiological Analysis Rate to 79.2 Percent

    29 shares
    Share 12 Tweet 7
  • LLM-Driven Social Simulations Face Significant Epistemic Validity Challenges

    29 shares
    Share 12 Tweet 7
  • Veterinary Brucellosis Testing Requires Validated Decision Rules Across Animal Populations

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

Review finds disease prevention guidance prioritizes genetic risk over modifiable factors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.